Inhaled long-acting bronchodilators increase heart disease risk in COPD patients


eMediNexus    03 January 2018

New use of inhaled long-acting bronchodilators (long-acting β2-agonists [LABAs] or long-acting antimuscarinic antagonists [LAMAs]) in patients with chronic obstructive pulmonary disease (COPD) is associated with 1.5-fold increase in the risk of cardiovascular disease (CVD) within a month of starting treatment. These findings from an observational study were published online January 2, 2018 in JAMA Internal Medicine.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.